Abstract
Human Polo-like kinase 1 (Plk1) is an essential regulator of mitotic progression. Targeted inhibition of this kinase was effective in killing tumor cells in vitro and in vivo. The Plk1 inhibitor BI_2536 was well tolerated and showed antitumor activity in the first clinical trials enrolling patients with advanced solid tumors and refractory or relapsed acute myeloid leukemia.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Archambault, V. and Glover, D.M. 2009. Polo-like kinases: conservation and divergence in their functions and regulation. Nat Rev Mol Cell Biol 10(4): 265–275.
Baum A, Garin-Chesa P, Gürtler U, Munzert G, Rudolph D (2007) Efficacy of BI 2536, a potent and selective inhibitor of the mitotic kinase Plk1, in models of human non-small cell lung carcinoma. 12th World Conference on Lung Cancer, Seoul, South Korea. J Thorac Oncol 2(8 Suppl 4):S435–S436
Ellis PM, Chu QS, Leighl NB, Laurie SA, Trommeshauser D, Hanft G et al (2008) A phase I dose escalation trial of BI 2536, a novel Plk1 inhibitor, with standard dose pemetrexed in previously treated advanced or metastatic non-small cell lung cancer (NSCLC). J Clin Oncol (Meeting Abstracts) 26:8115
Engelbert D, Schnerch D, Baumgarten A, Wäsch R (2008) The ubiquitin ligase APC(Cdh1) is required to maintain genome integrity in primary human cells. Oncogene 27:907–917
Garcia-Higuera I, Manchado E, Dubus P, Canamero M, Mendez J, Moreno S et al (2008) Genomic stability and tumour suppression by the APC/C cofactor Cdh1. Nat Cell Biol 10:802–811
Lenart P, Petronczki M, Steegmaier M, Di Fiore B, Lipp JJ, Hoffmann M et al (2007) The small-molecule inhibitor BI_2536 reveals novel insights into mitotic roles of polo-like kinase 1. Curr Biol 17:304–315
Morgan DO (2007) The cell cycle: principles of control. New Science, London, United Kingdom
Mross K, Frost A, Steinbild S, Hedbom S, Rentschler J, Kaiser R et al (2008) Phase I dose escalation and pharmacokinetic study of BI 2536, a novel polo-like kinase 1 inhibitor, in patients with advanced solid tumors. J Clin Oncol 26(34): 5511–5517
Petronczki M, Lenart P, Peters JM (2008) Polo on the rise-from mitotic entry to cytokinesis with Plk1. Dev Cell 14:646–659
Steegmaier M, Hoffmann M, Baum A, Lenart P, Petronczki M, Krssak M et al (2007) BI 2536, a potent and selective inhibitor of polo-like kinase 1, inhibits tumor growth in vivo. Curr Biol 17: 316–322
Strebhardt K, Ullrich A (2006) Targeting polo-like kinase 1 for cancer therapy. Nat Rev Cancer 6: 321–330
Sunkel CE, Glover DM (1988) Polo, a mitotic mutant of drosophila displaying abnormal spindle poles. J Cell Sci 89(Pt 1):25–38
Uchiumi T, Longo DL, Ferris DK (1997) Cell cycle regulation of the human polo-like kinase (PLK) promoter. J Biol Chem 272:9166–9174
van de Weerdt BC, Medema RH (2006) Polo-like kinases: a team in control of the division. Cell Cycle 5:853–864
Von Pawel J, Reck M, Digel W, Kortsik C, Thomas M, Frickhofen N et al (2008) Randomized phase II trial of two dosing schedules of BI 2536, a novel Plk-1 inhibitor, in patients with relapsed advanced or metastatic non-small-cell lung cancer (NSCLC). J Clin Oncol (Meeting Abstracts) 26:8030
Wäsch R, Engelbert D (2005) Anaphase-promoting complex-dependent proteolysis of cell cycle regulators and genomic instability of cancer cells. Oncogene 24:1–10
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2010 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Wäsch, R., Hasskarl, J., Schnerch, D., Lübbert, M. (2010). BI_2536 - Targeting the Mitotic Kinase Polo-Like Kinase 1 (Plk1). In: Martens, U. (eds) Small Molecules in Oncology. Recent Results in Cancer Research, vol 184. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-01222-8_15
Download citation
DOI: https://doi.org/10.1007/978-3-642-01222-8_15
Published:
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-01221-1
Online ISBN: 978-3-642-01222-8
eBook Packages: MedicineMedicine (R0)